Italy

Achilles Vaccines

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19

Lead Product(s): Malaria vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: The EU Malaria Fund

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding June 19, 2020

Details:

The investment supports development of a novel Malaria vaccine on Achilles versatile technology platform to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. To also supports produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines.

ReiThera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine

Lead Product(s): Adenoviral vector-based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Univercells

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 23, 2020

Details:

The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

Takis Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models

Lead Product(s): Linear DNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

The vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Achilles Vaccines

Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19

ReiThera

ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine

Takis Biotech

Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models